
Innovative Biopharmaceutical Manufacturer
July 7,Northland(430047) The announcement shows that the company received the "Acceptance Notice" (DF20230707002) issued by the Beijing Stock Exchange on July 7, 2023. After reviewing the application documents for the issuance of shares to specific objects submitted by the company, the Beijing Stock Exchange determined that the application complies with the relevant requirements of the "Beijing Stock Exchange Listed Company Securities Issuance and Listing Review Rules" and has accepted it.
On June 5, 2023, Northland announced the "2023 Private Placement Stock Offering Prospectus (Draft)." The prospectus shows that Northland plans to raise no more than 250 million yuan through a private placement of stock. The funds are intended for drug research and development projects, biopharmaceutical industrialization projects, and more.
This article is from "Wabei.com",Author: Zhou Luyao, published by 36Kr with authorization."